A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice

Consumer Choice Between Common Generic and Brand Medicines in a Country with a Small Generic Market

“…22,23 Comparable results were found in Spain, another country with a small generic market. 24 In the current study, we see opportunity for educating consumers about the equivalence of generic versus original brand medicines, especially in older and lowereducated consumers. Educational outreach could enhance consumer knowledge and also empower consumers to better manage their medicine use.…”

“…17,24,25,27,32 The factors that influence the evolution of generic market share are diverse and country specific. In that regard, we cannot ignore the large influence of original brand-producing companies on the evolution of Belgian pharmaceutical sales.…”

Knowledge, attitudes and use of generic medicines: a cross sectional study among patients in Marcory-Treichville Health District Cote d’Ivoire

“…The link between the level of knowledge of GMs and their acceptance was shown in a study carried out by Valles et al in which short information of the patient on generic medicine made it possible to double the rate of substitution from 2.8 to 5.9% (Valles et al, 2003).…”

Comparing the Efficacy of 8 Week Treatment of Cipram® and its Generic Citalopram in Patients with Mixed Anxiety-Depressive Disorder

“…Also demonstration of the bioequivalence of the generic drug within an acceptable range with the original brand is required (20). Despite the lack of evidence for inferiority of generic drugs to their branded counterparts, many patients may resist changing from a brand name drug to its generic equivalent (10). Even some physicians may not believe in the same efficacy of the brand name and generic drugs.…”

“…However, use of SSRIs in the treatment of MADD has not been evaluated widely. Since a considerable amount of total medical expenditure is made up of pharmaceutical expenditure, recently changing from more expensive brands to their generic drugs have been widely encouraged by authorities (9)(10)(11); this is considered a way to reduce healthcare expenditure (11). For example in the United States of America, total budget devoted to antidepressants increased in a 13 year period (1991 -2004) from 159$ million to 2.26$ billion but after the entrance of cheaper generic fluoxetine and paroxetine in 2001 and 2003, respectively, this amount decreased to 1.99$ billion in 2005 (6).…”